Eikon Therapeutics JP Morgan Biotech Call Series
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, and thank you for standing by. I would like to inform all participants that this conference call, as well as any Q&A, may be recorded and made available to clients of J.P. Morgan. Where companies presenting any recording may also be posted on their website. Views and opinions expressed by any external speakers on this call are those of the speakers and not of J.P. Morgan. Parts of this conference call may also be reproduced in the J.P. Morgan research. Participants are prohibited from posting, sharing, or distributing any parts of this call or its contents on social media or any public forums without prior written consent from J.P. Morgan. If you have any objections, you may disconnect at this time. This call is intended for J.P. Morgan clients only. Press participants are not permitted on this call and should disconnect now.
Members of J.P. Morgan Global Banking Department may be present on this call. I would now like to turn the call over to Brian Cheng.
You may proceed. Good afternoon, everyone, and thanks, operator.
Thanks for joining us for another installment of the biotech call series here. I'm Brian Cheng. I'm one of the Senior Research Biotech Analysts here at J.P. Morgan. Joining us today is Eikon Therapeutics. On the call with us is Eikon CEO, Roger Perlmutter. Roger, thank you so much for hopping on the call here. You and I just met days ago, lots to talk about just on the back of the data drops at ESMO. For those of us who are in the audience today who are not super familiar with the story at Eikon, can you give us a quick overview of the story, what you're working on, and maybe give us a quick overview of what we should expect now in the next 6-12 months?
Thank you. Super, Brian. Thanks so much for giving me this opportunity, and welcome everyone who's joined.
Eikon Therapeutics is a late-stage clinical development company. We have multiple programs in the clinic. All of them are in oncology at this point, and all of them at the moment are generating data at the very high end of expectation. The company was founded, though, on a platform which was applying super-resolution microscopy to problems in biochemistry and molecular biology. Our platform permits us to visualize individual proteins in living cells in a nondestructive way with roughly 10 nanometer or so spatial resolution and sub-millisecond time resolution when we want it. It turns out that that's an extremely informative way to visualize processes in cells that ultimately affect physiologic processes in humans. Over time, the platform will be the greatest contributor to value.
We are developing drugs that have come directly from the platform, which permits us to identify targets that elude others and to prosecute targets that others simply can't pursue. The principal focus in the last year or so has been the clinical data that we're generating, and we're quite a large clinical program. We have roughly 1,000 patients under study in multiple clinical trials in oncology, as I say. You can expect that because of the scale of those trials and the fact that they are ongoing and delivering data, that over the next 6-12 months, there will be additional data from each one of those, which include trials in advanced melanoma, non-small cell lung cancer, breast, ovarian, prostate cancer, and in patients in particular who have defective DNA damage repair or mismatch repair.
All of those are areas where we have substantial expertise, have prosecuted targets previously, and where I think we're making real progress.
That's a great start. Let me just looking at TLR7/8 first. As we think about what you presented at ESMO, and I think a lot the prior data cut also came from ESMO, can you talk about just the breadth of the data that you've seen so far? What disruption that you see TLR7/8 could bring to the non-small cell lung cancer space?
Sure. I think it's important to put the TLR7/8 program, which is EIK1001, to put that in context, and the context is a long one historically. It began many years ago when I first had the opportunity to look at data from the molecule that became KEYTRUDA. When I arrived at Merck, it was interesting to see that an antibody directed against PD-1, and this is, of course, now goes back a long ways in history, an antibody directed against PD-1 seemed to have activity not just in what we thought of as immunologically active tumors like malignant melanoma, but also in non-small cell lung cancer, where immune responses against the tumor were not felt to play a terribly big role. And ultimately, we pursued that quite aggressively.
In fact, at the time when I was leading research and development at Merck, my feeling was we were viewing something that was unprecedented, and it was our responsibility to attempt to enumerate the full breadth of response that could be triggered in patients with malignant disease. We began what became an enormous program, the largest program ever in clinical oncology. KEYTRUDA, of course, has become an extremely successful drug and something that has made a big difference for an awful lot of people around the world. It's a fundamental tool in the therapeutic armamentarium, but the fact remains that the minority of patients respond in most cases. The question from the beginning had been, what's wrong with those people who don't respond? Why is it that there are such good responses in many cases, yet other patients don't respond at all?
That led us to do a variety of combination studies, and those combination studies were well-informed by the data that we were obtaining from the clinical analyses. What I can tell you is that pro-inflammatory signals in the tumor seem to be very important, and we sought to increase those pro-inflammatory tumors through the application of chemotherapy, which is a powerful pro-inflammatory stimulus through cell death, and that became the standard of care in non-small cell lung cancer. Those were the KEYNOTE-189 and KEYNOTE-407 studies in non-squamous and squamous cell carcinoma in particular. We did a lot of other studies as well, but my feeling was that there was still more opportunity to trigger, to enhance inflammatory responses that could make KEYTRUDA an even more powerful drug and permit more patients to respond.
One of the things that we were interested in was the question of whether innate immunity triggered through toll-like receptors, in particular TLR7 and eight, could be harnessed in this setting. The problem with these toll-like receptors is that they're very potent agonists for inflammatory response. If you trigger TLR7/8 agonism systemically, there's a high risk of what's called cytokine release syndrome, which is a very significant adverse experience and can, in severe cases, be fatal. We began studies of systemic administration of TLR7/8, working with a small company partner, which was called Seven and Eight Biopharmaceuticals, back at Merck. Those studies made plain to us that it was possible to administer a TLR agonist systemically if you paid attention to good pharmaceutical practice.
Since that time, now, we at Eikon, standing on the shoulders of the work that was done at Merck, we, having licensed the TLR7/8 dual agonist, we have in total more than 600 patients whom we've treated with that molecule, and we are very comfortable with the safety profile, and so are regulatory agencies around the world. We've taken that into malignant melanoma, of course, a responsive tumor generally, and we are in a seamless phase II/III registration-enabling study. We did the same sort of thing in non-small cell lung cancer, but to do that study, we had to first demonstrate that it was safe to give a systemically administered TLR7/8 agonist in combination with chemotherapy. We had not done that before, and so we began a phase II study, which is called TeLuRide-005, but the name isn't important.
The important thing is what we are doing is just combining the standard of care regimen, which is KEYTRUDA plus appropriate chemotherapy in non-small cell lung cancer, either squamous or non-squamous, in combination with EIK1001, the TLR7/8 agonist. The data for that phase II study have been. Small parts of it have been presented in various different forums, but at ESMO, we presented the mature data, particularly for the squamous cohort. Those mature data show an improvement in overall response rate beyond what we had expected, and in addition, a quite long duration of response. In fairness, I have to say this is a single-arm study. It cannot be directly compared with any other study. It is unfair to do these cross-study comparisons anyway.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
